title: An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.
abstract: Milk thistle (Silybum marianum) extracts, one of the most widely used dietary supplements, contain a mixture of six major flavonolignans (silybin A, silybin B, isosilybin A, isosilybin B, silychristin, and silydianin) and other components. However, the pharmacokinetics of the free individual flavonolignans have been only partially investigated in humans. Furthermore, antioxidant effects of the extract, which may underlie the basis of many therapeutic effects, have not been thoroughly assessed. The present study evaluated the pharmacokinetics of the six major flavonolignans in healthy volunteers receiving single doses of either one (175 mg), two (350 mg), or three (525 mg) milk thistle capsule(s) on three separate study visits. Additionally, the steady-state pharmacokinetic parameters were determined after the subjects were administered one capsule three times daily for 28 consecutive days. Our results demonstrated that all six flavonolignans were rapidly absorbed and eliminated. In order of abundance, the exposure to free flavonolignans was greatest for silybin A followed by silybin B, isosilybin B, isosilybin A, silychristin, and silydianin. The systemic exposure to these compounds appeared linear and dose proportional. The disposition of flavonolignans was stereoselective, as evidenced by the apparent clearance of silybin B, which was significantly greater than silybin A, whereas the apparent clearance of isosilybin B was significantly lower than isosilybin A. The concentrations of urinary 8-epi-prostaglandin F2α, a commonly used biomarker of oxidative status in humans, were considerably decreased in study subjects after a 28-day exposure to the extract (1.3 ± 0.9 versus 0.8 ± 0.9 ng/mg creatinine) but failed to reach statistical significance (P = 0.076).
authors.affiliation: Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.
authors.forename: Hao-Jie
authors.initials: HJ
authors.lastname: Zhu
authors.forename: Bryan J
authors.initials: BJ
authors.lastname: Brinda
authors.forename: Kenneth D
authors.initials: KD
authors.lastname: Chavin
authors.forename: Hilary J
authors.initials: HJ
authors.lastname: Bernstein
authors.forename: Kennerly S
authors.initials: KS
authors.lastname: Patrick
authors.forename: John S
authors.initials: JS
authors.lastname: Markowitz
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000493:pharmacokinetics*; D015237:Dinoprost / Q000031:analogs & derivatives / Q000378:metabolism / Q000652:urine; D028441:F2-Isoprostanes / Q000378:metabolism / Q000652:urine; D005260:Female; D044947:Flavonolignans / Q000493:pharmacokinetics*; D064368:Healthy Volunteers; D006801:Humans; D008297:Male; D020944:Silybum marianum / Q000737:chemistry; D000077385:Silybin; D012838:Silymarin / Q000031:analogs & derivatives / Q000493:pharmacokinetics*; D055815:Young Adult
chemical_list: D000975:Antioxidants; D028441:F2-Isoprostanes; D044947:Flavonolignans; D012838:Silymarin; C075750:8-epi-prostaglandin F2alpha; D000077385:Silybin; C015505:silidianin; D015237:Dinoprost; C523198:isosilybin A; C015504:silychristin